Nemvaleukin alfa clinical trials
Also written ALKS 4230.
How each study uses nemvaleukin alfa has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses nemvaleukin alfa has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedPhase 3Mural Oncology, IncNCT05092360Written as Nemvaleukin and Pembrolizumab CombinationHow we knowReport a problem
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedPhase 2Mural Oncology, IncNCT04830124Written as Nemvaleukin Alfa SubcutaneousHow we knowReport a problem
- A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsCompletedPhase 1/2Mural Oncology, IncNCT02799095Written as ALKS 4230How we knowReport a problem
- A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedPhase 2Mural Oncology, IncNCT04144517Written as Nemvaleukin AlfaHow we knowReport a problem
- Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingPhase 1/2Mural Oncology, IncNCT04592653Written as Nemvaleukin alfaHow we knowReport a problem
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedPhase 1/2Mural Oncology, IncNCT03861793Written as ALKS 4230How we knowReport a problem
Tested with established drugs · 6 — they are given beside it
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedPhase 3Mural Oncology, IncNCT05092360Written as Nemvaleukin and Pembrolizumab CombinationHow we knowReport a problem
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedPhase 2Mural Oncology, IncNCT04830124Written as Nemvaleukin Alfa SubcutaneousHow we knowReport a problem
- A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsCompletedPhase 1/2Mural Oncology, IncNCT02799095Written as ALKS 4230How we knowReport a problem
- A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedPhase 2Mural Oncology, IncNCT04144517Written as Nemvaleukin AlfaHow we knowReport a problem
- Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingPhase 1/2Mural Oncology, IncNCT04592653Written as Nemvaleukin alfaHow we knowReport a problem
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedPhase 1/2Mural Oncology, IncNCT03861793Written as ALKS 4230How we knowReport a problem
Codes
What other systems call nemvaleukin alfa · ClinicalTrials.gg INT015561
- UNII (FDA) 7ZX1Q9SJ1FNEMVALEUKIN ALFAOne source FDA
- NCI Thesaurus C128107Nemvaleukin AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7ZX1Q9SJ1F | NEMVALEUKIN ALFA | One source FDA |
| NCI Thesaurus | C128107 | Nemvaleukin Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.